Immunocore Holdings plc
Immunocore Holdings plc（IMCR）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · IMCR · 截至 2025年9月30日
股东结构概览
144
机构持有人数
$1.79B
机构持仓总市值
▲ $288.00M vs Q2
50.83M
总流通股
freeFloat 99.04%
49.78M
13F 申报持股数
▲ 1.42M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
IMCR 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 7.06M | 14.05% | 14.05% | $256.63B | Nov 14, 2025 | ▼ 3.8K |
RTW INVESTMENTS, LP biological products, (no diagnostic substances) | 4.87M | 9.68% | 9.68% | $176.92B | Nov 14, 2025 | — held |
WELLINGTON MANAGEMENT GROUP LLP biological products, (no diagnostic substances) | 4.78M | 9.51% | 9.51% | $173.69B | Nov 14, 2025 | ▲ 567.3K |
FMR LLC biological products, (no diagnostic substances) | 4.42M | 8.79% | 8.79% | $160.59B | Nov 13, 2025 | ▼ 435.4K |
PRIMECAP MANAGEMENT CO/CA/ biological products, (no diagnostic substances) | 3.75M | 7.47% | 7.47% | $136.40B | Nov 12, 2025 | ▼ 16.9K |
BELLEVUE GROUP AG biological products, (no diagnostic substances) | 2.80M | 5.56% | 5.56% | $101.61B | Nov 14, 2025 | ▲ 355.0K |
BAKER BROS. ADVISORS LP biological products, (no diagnostic substances) | 2.32M | 4.62% | 4.62% | $84.38B | Nov 14, 2025 | — held |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 2.31M | 4.58% | 4.58% | $83.76B | Nov 14, 2025 | ▲ 200.0K |
DEEP TRACK CAPITAL, LP biological products, (no diagnostic substances) | 1.80M | 3.58% | 3.58% | $65.39B | Nov 14, 2025 | — held |
BVF INC/IL biological products, (no diagnostic substances) | 1.57M | 3.13% | 3.13% | $57.19B | Nov 14, 2025 | ▲ 550.0K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
25
增持
+4.73M 股1
新建仓
首次建仓17
减持
−1.80M 股0
清仓
完全退出净股数变化（前50家）
+2.93M
+4.73M / −1.80M
净新增持仓人
+9
新建 1 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
IMCR 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
6
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Ratcliffe Peter John director | May 27, 2026 | Award | 27,492 | $28.52 | $784.1K | 27.5K | Form 4 ↗ |
Peterson Kristine director | May 27, 2026 | Award | 27,492 | $28.52 | $784.1K | 27.5K | Form 4 ↗ |
Pao William director | May 27, 2026 | Award | 27,492 | $28.52 | $784.1K | 27.5K | Form 4 ↗ |
Kaul Siddharth director | May 27, 2026 | Award | 27,492 | $28.52 | $784.1K | 27.5K | Form 4 ↗ |
Herbst Roy Steven director | May 27, 2026 | Award | 27,492 | $28.52 | $784.1K | 27.5K | Form 4 ↗ |
Bell John Irving director | May 27, 2026 | Award | 27,492 | $28.52 | $784.1K | 27.5K | Form 4 ↗ |
Coy Travis Alan Chief Financial Officer | Feb 17, 2026 | Award | 95,637 | $32.38 | $3.10M | 95.6K | Form 4 ↗ |
Coy Travis Alan Chief Financial Officer | Feb 17, 2026 | Award | 33,353 | — | — | 33.4K | Form 4 ↗ |
Jallal Bahija CHIEF EXECUTIVE OFFICER | Feb 17, 2026 | Award | 395,066 | $32.38 | $12.79M | 395.1K | Form 4 ↗ |
Jallal Bahija CHIEF EXECUTIVE OFFICER | Feb 17, 2026 | Award | 88,573 | — | — | 88.6K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Immunocore Holdings plc（IMCR）主要由机构投资者持有，机构持股比例约为 97.9%。公司内部人员持股约 0.96%，散户及公众持股约占剩余的 1.10%。
Immunocore Holdings plc 最大机构股东为 T. ROWE PRICE INVESTMENT MANAGEMENT, INC.，截至 September 30, 2025 持有约 7.06 million 股，占总流通股的 14.05%。
目前共有 144 家机构持有 IMCR 股票，合计持仓市值约 $1.79 billion，数据来源为最新 SEC 13F 申报。
常见问题
IMCR ownershipImmunocore Holdings plc（IMCR）主要由机构投资者持有，机构持股约 97.9%。最大股东为 T. ROWE PRICE INVESTMENT MANAGEMENT, INC.，持股比例 14.05%。内部人员持股约 0.96%。数据来源 SEC Form 13F，截至 September 30, 2025。